YAVNE, Israel, Sept. 04, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated
biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced
that the Company will present a corporate overview at the 13th Annual Wells Fargo Securities Healthcare Conference
taking place from September 5-6, 2018 at the Westin Copley Place in Boston. Gal Cohen, President and Chief Executive Officer, will
deliver MediWound’s presentation on Thursday, September 6th at 1:20 p.m. Eastern time.
Mr. Cohen’s presentation will be webcast live on the internet and can be accessed by visiting the Investor
Relations section of the Company’s website at www.mediwound.com. A replay of the webcast will be archived on the MediWound website for 90 days
following the presentation.
About MediWound Ltd.
MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and
commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of
severe burns, chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid®,
received marketing authorization from the European Medicines Agency as well as the Israeli, Argentinian and South Korean Ministries
of Health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns.
NexoBrid® represents a new paradigm in burn care management, and clinical trials have demonstrated, with
statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable
tissues.
MediWound's second innovative product, EscharEx® is a topical biological drug being developed for
debridement of chronic and other hard-to-heal wounds and is complementary to the large number of existing wound healing products,
which require a clean wound bed in order to heal the wound. EscharEx® contains the same proteolytic enzyme technology as
NexoBrid®, and benefits from the wealth of existing development data on NexoBrid®. In two Phase 2
studies, EscharEx® has demonstrated safety and efficacy in the debridement of chronic and other hard-to-heal wounds,
within a few daily applications.
For more information, please visit www.mediwound.com.
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of
1933, as amended, Section 21E of the US Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as
statements regarding assumptions and results related to the regulatory authorizations and launch dates. In some cases, you can
identify forward-looking statements by terminology such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,”
“should,” “plan,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking
statements are based on MediWound’s current knowledge and its present beliefs and expectations regarding possible future events and
are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those
anticipated in these forward-looking statements as a result of several factors. In particular, you should consider the risks
discussed under the heading “Risk Factors” in our annual report on Form 20-F for the year ended December 31, 2017 and information
contained in other documents filed with or furnished to the Securities and Exchange Commission. You should not rely upon
forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and
circumstances reflected in the forward-looking statements will be achieved or will occur. The forward-looking statements made
herein speak only as of the date of this announcement and MediWound undertakes no obligation to update publicly such
forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
